Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients

European Respiratory Journal

Volumn 19, Issue 4, 2002, Pages 743-755

  Reichenberger, F ^a   Habicht, J M ^a   Gratwohl, A ^a   Tamm, M ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Antifungal therapy; Diagnosis; Invasive pulmonary aspergillosis; Neutropenia; Surgery; Treatment

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CASPOFUNGIN; CLOTRIMAZOLE; FLUCONAZOLE; FLUCYTOSINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MICONAZOLE; NIKKOMYCIN; NYSTATIN; PAPULACANDIN DERIVATIVE; POSACONAZOLE; TERPENOID; VORICONAZOLE;

CAUSE OF DEATH; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; ELECTROLYTE DISTURBANCE; FEBRILE NEUTROPENIA; GRANULOCYTE TRANSFUSION; HIGH RISK PATIENT; HISTOLOGY; HUMAN; KIDNEY FAILURE; LUNG ASPERGILLOSIS; LUNG RESECTION; MICROBIOLOGY; MORBIDITY; MORTALITY; NAUSEA AND VOMITING; NEPHROTOXICITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SERODIAGNOSIS; SIDE EFFECT;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; ASPERGILLOSIS; AZOLES; BRONCHOSCOPY; CYTOKINES; DIAGNOSTIC IMAGING; HUMANS; LUNG DISEASES, FUNGAL; NEUTROPENIA; PNEUMONECTOMY; SEROLOGIC TESTS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0036203652     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.02.00256102     Document Type: Review

References (142)

1. Antifungal and surgical treatment of invasive aspergillosis. Review of 2,121 published cases
2. Treatment and outcome of invasive aspergillus infections in allogeneic BMT recipients
3. Many faces of pulmonary aspergillosis
4. Macrophage inflammatory protein-1alpha is a critical mediator of host defense against invasive pulmonary aspergillosis in neutropenic hosts
5. Role of TNF-alpha in pulmonary host defense in murine invasive aspergillosis
6. Inhibition of the transcription factors NK-kB and AP-1 underlies loss of cytokine gene expression in rat alveolar macrophages treated with a diffusible product from the spores of aspergillus fumigatus
7. T Cell Vaccination in mice with invasive pulmonary aspergillosis
8. Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B
9. Combination immunotherapy and anti-fungal chemotherapy
10. The potential role of cytokine therapy for fungal infection in patients with cancer: Is recovery from neutropenia all that is needed?
11. Invasive aspergillosis. Disease spectrum, treatment practices, and outcome
12. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital
13. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients
14. Non-candida fungal infections after bone marrow transplantation: Risk factor and outcome
15. Epidemiology and diagnosis of invasive pulmonary aspergillosis in bone marrow transplant patients: Results of a 5 year retrospective study
16. Invasive mold infections in allogeneic bone marrow transplant recipients
17. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: Diagnosis and therapeutic outcome
18. Pathogenesis of pulmonary aspergillosis
19. Fungal infections in transplant recipients
20. Epidemiology of aspergillus infections in a large cohort of patients undergoing bone marrow transplantation
21. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: Before and after chemoprophylaxis and institution of HEPA filters
22. Aspergillus in immunocompromised paediatric patients: Association with building hygiene, design, and indoor air
23. An outbreak of invasive aspergillosis in a haematologic unit
24. Control of an outbreak of nosocomial aspergillosis by laminar air-flow isolation
25. Airborne fungal spore monitoring in a protective environment during hospital construction, and correlation with an outbreak of invasive aspergillosis
26. Concentration of airborne aspergillus compared to the incidence of invasive aspergillosis: Lack of correlation
27. Environmental sampling for aspergilli during building construction on a hospital site
28. Impact of air filtration on nosocomial aspergillus infection. Unique risk of bone marrow transplant recipients
29. Systemic fungal infections in patients with hematologic malignancies: Indications and limitations of the antifungal armamentarium
30. Lung resection for invasive pulmonary aspergillosis in neutropenic patients with hematologic diseases
31. Fatal haemoptysis in pulmonary filamentous mycosis: An underevaluated cause of death in patients with acute leukaemia in haematological complete remission. A retrospective study and review of the literature
32. Pulmonary cavitation and massive hemoptysis in invasive pulmonary aspergillosis. Influence of bone marrow recovery in patients with acute leukemia
33. Management of invasive pulmonary aspergillosis in hematologic patients: A review of 87 consecutive cases at a single institution
34. Radiologic-pathologic correlations of the CT halo sign in invasive pulmonary aspergillosis
35. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia
36. Invasive pulmonary aspergillosis: Prediction at thin section CT in patients with neutropenia - A prospective study
37. Pulmonary nodule and the CT halo sign
38. Accuracy of percutaneous lung biopsy for invasive pulmonary aspergillosis
39. Crescent sign in invasive pulmonary aspergillosis: Frequency and related CT and clinical factors
40. Invasive pulmonary aspergillosis in acute leukemia: Characteristic findings on CT, the CT halo sign, and the role of CT in early diagnosis
41. Invasive pulmonary aspergillosis. MRI, CT, and plain radiographic findings and their contribution for early diagnosis
42. Invasive aspergillosis in immunocompromised patients: Findings on plain film and (HR) CT
43. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomography scan and surgery
44. Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel noninvasive method for measuring response to antifungal therapy
45. Computed tomographic scan of the chest, latex agglutination test, and plasma (1->3)-β-glucan assay in early diagnosis of invasive pulmonary aspergillosis: A prospective study of 215 patients
46. Fungal pulmonary infections after bone marrow transplantation: Evaluation with radiography and CT
47. Aggressive surgical management in localized pulmonary mycotic and nonmycotic infections for neutropenic patients with acute leukemia: Report of eighteen cases
48. Comparison of an enzyme immunoassay and a latex agglutination system for the diagnosis of invasive aspergillosis in bone marrow transplant recipients
49. Sandwich enzyme-linked immunosorbent assay compared with pastorex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients
50. Specificity of a Sandwich enzyme-linked immunosorbent assay for detecting aspergillus galactomannan
51. Value of antigen detection in predicting invasive pulmonary aspergillosis
52. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis
53. Serum aspergillus galactomannan antigen testing by sandwich ELISA: Practical use in neutropenic patients
54. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: A prospective validation
55. Plasma (1->3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes
56. Use of recombinant mitogillin for improved serodiagnosis of aspergillus fumigatus-associated diseases
57. Aspergillus antigen detection in the diagnosis of invasive aspergillosis
58. PCR detection of DNA specific for aspergillus species in serum of patients with invasive aspergillosis
59. Comparison of serum galactomannan antigen detection and competitive polymerase chain reaction for diagnosing invasive aspergillosis
60. Early detection of aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening
61. Quantitative galactomannan detection is superior to PCR in diagnosing and monitoring invasive pulmonary aspergillosis in an experimental rat model
62. Detection and identification of fungal pathogens in blood by using molecular probes
63. Specific detection of aspergillus species in blood and bronchoalveolar lavage samples of immunocompromised patients by two step PCR
64. Detection of Aspergillus fumigatus by polymerase chain reaction
65. Development of two real-time quantitative TaqMan PCR assays to detect circulating Aspergillus fumigatus DNA in serum
66. Prediction of invasive pulmonary aspergillosis from colonisation of lower respiratory tract before marrow transplantation
67. Identification of aspergillus species using internal transcribed spacer regions 1 and 2
68. Bronchoalveolar lavage during neutropenic episodes: Diagnostic yield and cellular pattern
69. Bronchoalveolar lavage in the diagnosis of pulmonary complication of bone marrow transplantation
70. Diagnostic aspects of invasive aspergillus infections in allogeneic BMT recipients
71. The use of respiratory tract cultures in the diagnosis of invasive pulmonary aspergillosis
72. Diagnostic yield of bronchoscopy in histologically proven invasive pulmonary aspergillosis
73. Aspergillus antigen detection in bronchoalveolar lavage fluid from patients with invasive pulmonary aspergillosis and aspergillomas
74. Non-value of aspergillus antigen detection in bronchoalveolar lavage fluids of patients undergoing bone marrow transplantation
75. Comparison of antigen detection and PCR assay using bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients receiving treatment for hematological malignancies
76. The detection of aspergillus spp. by the polymerase chain reaction and its evaluation in bronchoalveolar lavage fluid
77. Detection of aspergillus species DNA in bronchoalveolar lavage samples by competitive PCR
78. Transbronchial biopsy in the diagnosis of pulmonary infiltrates in immunocompromised patients
79. Diagnostic and therapeutic thoracic surgery in leukemia and severe aplastic anemia
80. NIAID mycoses study group multicenter trial of oral intraconazole therapy for invasive aspergillosis
81. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin B, AMB lipid formulation, or azoles. 40th antimicrobial agents and chemotherapy
82. Invasive aspergillosis in severely neutropenic patients over 18 years: Impact of intranasal amphotericin B and HEPA filtration
83. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
84. Comparison of effects of amphotericin B desoxycholate infused over 4 or 24 hours: Randomised controlled trial
85. Therapeutic outcome in invasive aspergillosis
86. Aspergillus case fatality rate: Systematic review of the literature
87. Topical treatment of pulmonary aspergilloma by antifungals
88. Percutaneous treatment with amphotericin B of mycotic lung lesions from invasive aspergillosis: Result in 10 immunocompromised patients
89. Chronic necrotizing pulmonary aspergillosis treated by endobronchial amphotericin B
90. Fiberoptic local endobronchial instillation of antimycotic agents (Amphotericin B or Miconazol) as an additive treatment of invasive aspergillosis and aspergilloma of the lung
91. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever
92. Empiric antifungal therapy in febrile granulocytopenic patients
93. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia
94. The physiological effects of inhaled amphotericin B
95. Aerolized amphotericin B inhalations as prophylaxis of invasive aspergillosis infections during prolonged neutropenia: Result of a prospective randomized multicenter trial
96. Practice guidelines for diseases caused by aspergillus
97. Lipid formulations of amphotericin B: Clinical efficacy and toxicities
98. Liposomal amphotericin B, AmBisome
99. An EORTC international multicenter randomized trial comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis
100. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: A randomised, double-blind, placebo-controlled study
101. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis
102. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia
103. Overview of amphotericin B colloidal dispersion (Amphocil)
104. Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: Data of a prematurely stopped clinical trial
105. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases
106. A randomized, double-blind comparative trial evaluation the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia
107. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: Randomised study
108. Antifungal drug resistance in aspergillus
109. The exciting future of antifungal therapy
110. Treatment and developmental therapeutics in aspergillosis
111. Oral and intravenous itraconazole for systemic fungal infections in neutropenic haematological patients: Meeting report
112. Analysis of compassionate use intraconazole therapy for invasive aspergillosis by the NIAID mycoses study group criteria
113. Antifungal prophylaxis with itraconazole oral solution in neutropenic patients
114. Break-through invasive fungal infections in neutropenic patients after prophylaxis with itraconazole
115. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: A randomized double-blind, double-placebo, multicenter trial comparing amphotericin B
116. Itraconazole resistance in aspergillus fumigatus
117. Acquired itraconazole resistance in Aspergillus fumigatus
118. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model
119. Activity of voriconazole (UK-109,496) against clinical isolates of aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis
120. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever
121. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandines MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
122. Efficacy of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366 in an experimental model of invasive aspergillosis
123. Discovery of novel antifungal (1,3)-β-D-glucan synthesis inhibitors
124. Echinocandins and pneumocandins - A new antifungal class with a novel mode of action
125. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits
126. Comparison of in vitro activity of liposomal nystatin against aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposmal AB, AB lipid complex, and itraconazole
127. Antifungal agents: Chemotherapy target and immunologic strategies
128. Amphotericin B with and without itraconazole for invasive aspergillosis: A three-year retrospective study
129. Amphotericin B refractory aspergillosis after itraconazole: Evidence for significant antagonism
130. Amphotericin B versus Amphotericin B plus 5-Flucytosine: Poor Results in the Treatment of Proven Systemic Mycoses in Neutropenic Patients
131. Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor
132. Fatal haemoptysis induced by invasive pulmonary aspergillosis in patients with acute leukemia during bone marrow and clinical remission: Report of two cases and review of the literature
133. Invasive aspergillosis in neuropenic patients: Rapid neutrophil recovery is a risk factor for severe pulmonary complications
134. Granulocyte transfusions: Efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation
135. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: A pilot study
136. Operation for cavitating invasive pulmonary aspergillosis in immunocompromised patients
137. Surgical therapy for pulmonary aspergillosis in immunocompromised patients
138. Successful local excision and long-term survival for invasive pulmonary aspergillosis during neutropenia after bone marrow transplantation
139. Surgical aspects of resection for suspected invasive pulmonary fungal infection in neutropenic patients
140. Resection of invasive pulmonary aspergillosis in immunocompromised patients
141. Invasive pulmonary fungal infection in hematological patients: Is resection effective?
142. Prognostic factors of invasive pulmonary aspergillosis in leukemic patients